Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
68.7M
-
Shares change
-
+2.65M
-
Total reported value, excl. options
-
$1.39B
-
Value change
-
+$50.2M
-
Put/Call ratio
-
0.33
-
Number of buys
-
92
-
Number of sells
-
-62
-
Price
-
$20.26
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q3 2019
193 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q3 2019.
Coherus Oncology, Inc. - Common Stock (CHRS) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.7M shares
of 115M outstanding shares and own 59.55% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (6.57M shares), Temasek Holdings (Private) Ltd (6.56M shares), BlackRock Inc. (5.29M shares), JPMORGAN CHASE & CO (3.67M shares), FMR LLC (3.27M shares), Kohlberg Kravis Roberts & Co. L.P. (3.06M shares), VANGUARD GROUP INC (2.93M shares), LORD, ABBETT & CO. LLC (2.91M shares), STATE STREET CORP (2.78M shares), and Rubric Capital Management LP (2.04M shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.